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ABSTRACT
Background: Dietary supplementation with unique prebiotic nondigestible carbohydrates has been shown to
suppress allergy. In the present study, the prophylactic efficacy of a disaccharide β-1, 4 mannobiose (MNB) in a
BALBC mouse model of intranasally-induced pollen allergy was characterized.
Methods: Balbc mice were pretreated with MNB orally and sensitized with pollen extract intraperitoneally and
intranasally and challenged with histamine and crude pollen extract. Outcomes were measured as clinical
signs, antibody isotypes, cytokine gene and protein expression patterns.
Results: The MNB-treated mice had lower sneezing frequency as compared to the positive control mice (P <
0.05). The low dose MNB-treated mice had less histamine (P < 0.05). However, the Cry j1 and Cry j 2-specific
IgE, IgG, IgG1 and IgG2a antibody activity did not differ between groups (P > 0.05). The MNB-treated mice had
increased IFN-γ (P < 0.05), and decreased IL-4 (P < 0.05). Mice in the high dose group had increased IL-10 (P
< 0.05). However, TGF-β and IL-17 concentration did not differ between groups (P > 0.05). Both total and Cry j1
and Cry j 2-specific IgA were increased in the high dose group. Real-time RT-PCR analysis indicated that IL-4
and IL-17 mRNA expression were lower in MNB-treated mice (P < 0.05).
Conclusions: This work provides insights into using MNB as a potential prebiotic immunomodulator via de-
creased clinical signs, improved type1type 2 balance, and IgA production, thus validating the potential use of
MNB as a prophylactic prebiotic candidate to attenuate allergic response.
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ABBREVIATIONS
APC, Antigen-Presenting Cells; Cj, Cryptomeria Japonica; CT, Cholera Toxin; ELISA, Enzyme-Linked Immuno-
Sorbent Assay; FOXP3, Forkhead Box Protein 3; IFN-γ, Interferon γ; Ig, Immunoglobulins; IL, Interleukin;
MALT, Mucosa-Associated Lymphoid Tissue; MNB, β-1, 4 mannobios; PBS, Phosphate Buffered Saline;
RORγT, Retinoic Acid-Related Orphan Receptor; RT-PCR, Reverse-Transcription Polymerase Chain Reaction;
TGF, Transforming-Growth Factor; Th, T Helper Cell; TLR, Toll Like Receptor; Treg, T Regulatory Cell.
INTRODUCTION
Pollinosis caused by Japanese cedar (Cryptomeria ja-
ponica, Cj) pollen is a serious disease of concern that
is prevalent in 10-20% of the population and poses a
major public health problem.1 The clinical signs of Cj
pollinosis in humans are characterized by sneezing,
watery rhinorrhea and conjunctivitis.2 Allergens Cry j
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1 and Cry j2 have been isolated earlier and are re-
ported as the two dominant allergens responsible for
causing Cj pollen allergy.3 Although many people suf-
fer from Cj pollinosis, an effective therapy to attenu-
ate and cure the clinical signs has not been estab-
lished yet. Anti-histamine and steroid drug remedies
have been widely used to suppress the allergic signs,
however these have been shown to have various side
effects and cause inconvenience.4 Therefore, it is im-
portant to develop an effective prophylactic approach
without any side effects to prevent Cj pollinosis.
Dietary interventions with prebiotic nondigestible
carbohydrates have been shown to reduce the devel-
opment of allergic disease.5-8 There are several major
prebiotics including oligofructose, inulin, galactooli-
gosaccharides, and fructooligosaccharides, which
have been widely used to stimulate the growth of par-
ticular bacterial species and improve host health.9
Studies in infants with allergy, fed such prebiotic for-
mulae demonstrated a reduced risk of expression of
allergy.10 Similar antiallergic effects induced by oligo-
saccharides have also been demonstrated in animals
sensitized with ovalbumin6 or cow milk proteins.11
Much recent research showed that oligosaccharides
suppressed cow milk allergy in mice by induction of
regulatory T (Treg) cells,7 indicating that the inhibi-
tion of allergic signs were not solely due to decrease
in type-2 and increase in type-1 stimulation. However,
the beneficial effect of prebiotics, in particular using
short chain disaccharides for suppression of pollen al-
lergic response has not been widely investigated in
detail, which intrigued us to carry out this study.
The β-1, 4 mannobiose is a disaccharide derived
from a coconut meal enzymatic hydrolysate, which
contained approximately 13% β-1, 4 mannobiose and
only residual mannose (<3% mannose, Fuji Oil,
Osaka, Japan). Mannobiose is more water soluble
and more homogenous than the large mannose-
containing molecules like mannooligosaccharides. It
was reported earlier that MNB may be potential
ligands for TLR24.12 We previously observed that
supplementation of mannobiose during the early
stage of broiler production was able to effectively re-
duce gut Salmonella and chickens fed MNB had in-
creased IgA production and improved Salmonella en-
teritidis clearance,13 as well as MNB was able to up-
regulate the local expression of genes related to host
defence and enhances innate immunity thereby act-
ing as an immuno-modulator.14,15 These results sug-
gest that MNB may act as a potential immune-
modulating agent in suppression of pollen allergic re-
sponse. In the present study, we investigated the pro-
phylactic effect of β-1, 4 mannobiose in a BALBC
mouse model of intranasally-induced pollen allergy
and examined candidate immune response polarizers
involved in immune modulation.
METHODS
PREPARATION OF β-1, 4 MANNOBIOSE
Pure β-1, 4 mannobiose (about 99% purity) was pre-
pared from Philippine coconut flour by enzymatic re-
actions and was provided by Fuji Oil.
PRETREATMENT WITH MNB, ANIMAL SENSITI-
ZATION AND CHALLENGE
A total of forty-eight BALBC female mice (6-7 weeks
old) were purchased from Charles River laboratories
(Montreal, QC, Canada) and randomly divided into 4
groups of twelve mice in two cages as described in
Figure 1 and as follows: Negative control; Positive
control; MNB low dose treated group and MNB high
dose treated group. All animals were housed in the
campus animal facility at the University of Guelph in
a 12-h lighting cycle and fed a diet (Harlan Teklad
global diet, 14% protein and 3.5% fat, Madison, WI,
USA). Food and water were available ad libitum. All
procedures were performed in accordance with the
guidelines established by the Canadian Council of
Animal Care (CCAC) and approved by the Animal
Care Committee at the University of Guelph.
Following a 1-week adaptation period, mice in the
MNB low dose group and MNB high dose group
were given 5.0 and 20 mgkg bodyweight of MNB in
a 100 μL of PBS solution by oral gavage three times a
week throughout the experimental period, respec-
tively. All other groups were orally gavaged with 100
μL of PBS placebo solution. From the 7th week on-
wards, mice in the positive control group, MNB low
dose group, and MNB high dose group were intrape-
ritoneally injected with 50 μg pollen extract in 100 μL
of aluminum hydroxide gel adjuvant (alum) (2%, Al-
hydrogel, Westbury, CA, USA) once a week for 4
weeks. Mice in the negative control were intraperito-
neally (IP) injected with 100 μL of aluminum hydrox-
ide gel adjuvant (alum) (2%, Alhydrogel) once a week
for 4 weeks. Following the 4-week IP injection period,
mice in the positive control group, MNB low dose
group, and MNB high dose group were intranasally
sensitized with 25 μLmouse of a PBS solution con-
taining 50 μg of Japanese Cedar Pollen crude extract,
and 1 μg of cholera toxin (CT) (List Biologicals Labo-
ratories, Denver, CO, USA), twice a week for 2
weeks. The negative control group was orally gav-
aged according to an identical schedule, with 25 μL
mouse of a PBS solution containing 1 μg of CT. The
CT was used as an immunological adjuvant given to
mice by the intranasal route to enhance the immune
response.
In the 13th experimental week, all mice were in-
tranasally given 20 ng of histamine dihydrochloride
mouse once and intranasally challenged with 50 μg of
Japanese Cedar Pollen crude extract in 25 μL of PBS
a day later. The frequency of sneezing was measured
for 5 min using an unrestrained whole body plethys-
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Fig.　1　Experimental timeline: MNB oral administration, mice sensitization, and fi nal nasal challenge. 
Alum, aluminum hydroxide gel adjuvant; CT, cholera toxin; IP, intraperitoneal; MNB, β-1, 4 mannobiose; 
PBS, phosphate buffered saline.
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mograph post intranasal pollen challenge.16 Twenty-
four hours post the intranasal antigen challenge, all
mice were killed and whole blood and tissue samples
were collected.
TISSUE SAMPLING
Whole blood was collected by cardiac puncture and
kept at 4℃ overnight. Blood samples were then cen-
trifuged with 10,000 rpm for 10 min at 4℃ and sera
from each two mice were pooled in equal volumes
within each group, due to the limitation in volume.
Serum samples were frozen at -80℃ until further use.
Spleen was aseptically removed and stored in a 50-ml
conical tube with 10 ml of ice cold RPMI 1640 me-
dium (Gibco Invitrogen, Grand Island, NY, USA),
containing sodium bicarbonate (1.5 gL), glucose
(4.5 gL), L-glutamine (2 mM), sodium pyruvate (1
mM), penicillin (50 unitsmL), and streptomycin (50
μgmL), and splenocytes were isolated. Peyer’s
patches in the intestine were collected into a 2-ml
tube containing 1 ml of RNAlater solution and stored
at -80℃ for RNA isolation.
MEASUREMENT OF SERUM HISTAMINE CON-
CENTRATION AND mMCPT-1 MEASUREMENTS
At the end point of experiment, mice were killed and
whole blood samples were collected by cardiac punc-
ture, and sera from each two mice were pooled in
equal volumes within each group. Histamine concen-
trations were determined by ELISA using a commer-
cial kit (Histamine EIA, LDN Labor Diagnostika
Nord, Nordhon, Germany). Serum samples were di-
luted (1 : 10) with diluent buffer (provided in the kit)
prior to application onto the plate and were run in du-
plicate wells along with the histamine standards. The
mouse mast cell protease (mMCPT-1) concentration
was quantified by ELISA according to the manufac-
turer’s instructions (eBiosciences, San Diego, CA,
USA), and all the samples were diluted 1 : 10.
DETERMINATION OF SERUM TOTAL IgE AND
TOTAL IgG
Total IgE and total IgG antibody activity in serum
were determined by ELISA. Briefly, flat-bottom 96-
well ELISA plates (Corning, Corning, NY, USA) were
coated with 100 μl of purified rat anti-mouse IgE mon-
oclonal antibody (Caltag Laboratories, Burlingame,
CA, USA; RMGE00) or purified goat anti-mouse IgG
(EMD Biosciences, CA, USA) diluted 1 : 1000 in 50
mM sodium bicarbonate buffer (pH 8.5) at 4℃ over-
night. Plates were washed four times with 200 μl of
0.05% Tween 20 in phosphate bufferd saline (PBST)
and then blocked with 200 μl of 1% bovine serum al-
bumin (BSA) in phosphate bufferd saline (PBS) for
2 h at 37℃. The plates were washed four times with
200 μl of PBST and serum samples were diluted (1 :
20 for total IgE and 1 : 25,000 for total IgG) in 1% BSA
in PBST, and 100 μl of diluted samples and a dupli-
cate dilution series of recombinant mouse IgE (BD
Pharmingen, San Diego, CA, USA; 553413) as stan-
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dards were added to the wells and incubated for 1 h
at 37℃. The plates were washed four times with 200
μl of PBST. For determination of total IgE, monoclo-
nal anti-mouse IgE conjugated to biotin (Caltag;
RMGE15) was used in combination with avidin-horse
radish peroxidase (Av-HRP) conjugate (BD Pharmin-
gen), and color development was revealed by the ad-
dition of 3,3’,5,5’-tetramethylbenzidine (TMB) chro-
mogenic substrate (Sigma-Aldrich, St. Louis, MO,
USA). For determination of total IgG, polyclonal goat
anti-mouse IgG (Fab specific) conjugated to alkaline
phosphatase (Sigma-Aldrich) was employed followed
by the addition of p-nitrophenyl phosphate (pNPP,
Sigma-Aldrich). The reaction was terminated after 30
minutes by addition of 50 μlwell of 2N H2SO4, and
absorbance values were determined at 450 nm using
an ELISA microplate reader (Bio-Rad Laboratories,
Hercules, CA, USA).
DETERMINATION OF POLLEN ALLERGEN CRY
J 1 AND CRY J 2 SPECIFIC IgE, IgG, IgG1 AND
IgG2a IN SERUM
Pollen specific IgE, IgG, IgG1 and IgG2a antibody ac-
tivity in serum samples were determined by sand-
wich ELISAs. Briefly, flat-bottom 96-well ELISA plates
(Corning) were incubated with 100 μlwell of 2.7 μg
mL of purified pollen allergen (Cry j 1 and Cry j 2,
Hayashibara Biochemical Laboratories, Okayama, Ja-
pan) in 100 mM of sodium bicarbonate buffer (pH
8.5) at 4℃ overnight. The plates were washed four
times with 200 μlwell of PBST. Mouse serum were
diluted in 1% BSA in PBST (1 : 5 for p pollen Cry j 1
and Cry j 2 specific IgE, 1 : 5000 for pollen Cry j 1 and
Cry j 2 specific IgG and IgG1, 1 : 2000 for pollen Cry j
1 and Cry j 2 specific IgG2a) and assays were dupli-
cated. For determination of pollen Cry j 1 and Cry j 2
specific IgE, monoclonal anti-mouse IgE conjugated
to biotin (Caltag) was used in combination with
avidin-horse radish peroxidase (Av-HRP) conjugate
(BD Pharmingen), and color development was re-
vealed by the addition of 3,3’,5,5’-tetramethy-
lbenzidine (TMB) chromogenic substrate (Sigma-
Aldrich). For determination of pollen Cry j 1 and Cry j
2 specific IgG, polyclonal goat anti-mouse IgG (Fab
specific) conjugated to alkaline phosphatase (Sigma-
Aldrich) was employed followed by the addition of p-
nitrophenyl phosphate (pNPP, Sigma-Aldrich). For
determination of pollen Cry j 1 and Cry j 2 specific
IgG1 and IgG2a, monoclonal rat anti-mouse IgG1 an-
tibody conjugated to biotin (1 : 2000) or anti-mouse
IgG2a conjugated to biotin (1 : 2000) (BD Pharmin-
gen) was added to the plates followed by incubation
avidin-horse radish peroxidase (Av-HRP) conjugate
(BD Pharmingen). Color development was revealed
by the addition of TMB substrate (Sigma-Aldrich).
The reaction was terminated after 30 minutes or
bright yellow solution showing up by addition of 50
μlwell of 2N H2SO4, and absorbance values were de-
termined at 450 nm using an ELISA microplate
reader (Bio-Rad Laboratories). The relative levels of
allergen-specific IgE, IgG, IgG1, and IgG2a in serum
were expressed as OD.
ALLERGEN-INDUCED CYTOKINE SECRETION
IN SPLEEN CELL CULTURES
Single cell suspensions were prepared by gently
grinding spleens using a syringe plunger and passing
the cells through a 100 μM nylon membrane cell
strainer (BD Biosciences, San Jose, CA, USA). The
spleen cell suspension was transferred onto a 15 mL
tube and subjected to centrifugation for 10 min at 100
× g. The supernatant was discarded, erythrocytes
were depleted by the addition of 1 mL of red blood
cell lysing buffer (Sigma-Aldrich), and the reaction
was stopped by adding 10 mL of sterile RPMI 1640
medium. After resuspension, the sample was centri-
fuged for another 10 min at 100 × g and washed twice
with 10 mL of RPMI 1640 medium. The splenocytes
were resuspended in RPMI 1640 medium supple-
mented with 8% fetal bovine serum (FBS) (Hyclone,
Fisher Scientific, Ottawa, ON, Canada), and cell vi-
ability was assessed by trypan blue exclusion. Cells
were cultured in 24-well plates (Corning) at a density
of 2.5 × 106mL in the absence (negative control
wells) or presence of pollen antigen (100 μgmL).
Supernatants were collected after 72 h of culture in
a 5% CO2 humidified incubator and assayed for the
presence of cytokines IFN-γ (Th1-biased), IL-4 (Th2-
biased), TGF-β and IL-10 (regulatory cytokines) and
IL-17 (Th17). The IFN-γ and IL-4 levels were meas-
ured by our previously established ELISA proce-
dure.17 All antibodies were purchased from BD
Pharmingen and the standard ranges of IFN-γ and IL-
4 are 1000-31.250 pgmL and 500-7.8 pgmL, respec-
tively. Regulatory cytokines TGF-β and IL-10 and
Th17 cytokine IL-17 were measured by ELISA with
the ELISA Ready-SET-Go! kits (eBioscience) accord-
ing to the manufacturer’s protocol. Each sample was
analyzed in duplicate. Cell proliferation was deter-
mined by WST-1 assay (Roche Diagnostics, Mann-
heim, Germany) following in vitro stimulation of
spleen cell cultures with pollen allergen (Cry j 1 and
Cry j 2). Briefly, 290 μl of RPMI 1640 medium with 8%
FBS and 10 μl of WST-1 solution were added into
each well after collection of supernatant and then the
24-well plate was incubated for 30 min at 37℃. The
supernatant was transferred into flat-bottom 96-well
ELISA plates (Corning) and absorbance was meas-
ured at 450 nm using an ELISA microplate reader
(Bio-Rad Laboratories).
DETERMINATION OF POLLEN-SPECIFIC IgA
AND TOTAL IgA IN FECAL PELLETS
Mouse fecal pellets were freshly collected on a
weekly basis from each mouse group cage and fecal
pellets from two cages in the same group were
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pooled and freeze-dried. A mass of roughly 1.0 g of fe-
cal pellets were added to 7 ml of PBS buffer in a 15-
mL conical tube and vortexed for 2 × 30 seconds.
Samples were subsequently centrifuged at 1600 × g
for 15 min at 4℃ to remove large fibrous particles
and supernatants were carefully collected in new
tubes (2 ml) and centrifuged at 7200 × g for 10 min at
4℃. The supernatant was collected for ELISA imme-
diately or stored at -80℃ for further experiments.
Concentrations of pollen-specific IgA were deter-
mined using an indirect ELISA. Flat-bottom 96-well
ELISA plates (Corning) were incubated with 100 μl
well of 2.7 μgmL purified pollen allergen (Cry j 1
and Cry j 2, Hayashibara Biochemical Laboratories)
in 100 mM of sodium bicarbonate buffer (pH 9.5) and
incubated overnight at 4℃. Plates were subsequently
washed four times with 200 μlwell of PBST, and
blocked with 200 μlwell of 1% BSA in PBS and incu-
bated for 2 h at 37℃. An additional four washes were
performed (200 μlwell of PBST) and 100 μlwell of
fecal extracts diluted in 1% BSA in PBST (1 : 2) were
added onto the plate in triplicate wells for a 2 h incu-
bation at 37℃. The plates were washed four times
with PBST and incubated with 100 μlwell of
biotinylated-monoclonal anti-mouse IgA (1 : 500; BD
Pharmingen) diluted in 1% BSA in PBST for 1 h at 37
℃. The wells were further washed four times with
200 μlwell of PBST, and 100 μlwell of avidin-horse
radish peroxidase (HRP) conjugate (1 : 2000; BD
Pharmingen) were applied onto the plate for 30 min
incubation at 37℃. After a final four-wash cycle with
PBST, pollen-specific IgA binding activity was re-
vealed by addition of 100 μlwell of 3,3’,5,5’-tetra-
methylbenzidine (TMB) substrate (Sigma-Aldrich).
The reaction was terminated after 30 min by addition
of 50 μlwell of 2N H2SO4, and absorbance values
were determined at 450 nm using an ELISA mi-
croplate reader (Bio-Rad Laboratories).
Total IgA levels in fecal sample were determined
by ELISA procedure. Flat-bottom 96-well ELISA
plates (Corning) were incubated with 100 μlwell of
diluted purified anti-mouse IgA antibody (1 : 1000;
BD Pharmingen; #556969) at 4℃ overnight. The
plates were washed four times with 200 μlwell of
PBST, and blocked with 200 μlwell of 1% BSA in
PBS and incubated for 2 h at 37℃. An additional four
washes were performed (200 μlwell of PBST) and
100 μlwell of fecal extracts diluted in 1% BSA in
PBST (1 : 2000) were added onto the plate in tripli-
cate wells for a 2 h incubation at 37℃. Purified mouse
IgA (BD Pharmingen, #553476) as standards were
added to the plate for generation of a standard curve
to calculate concentration of unknown samples. The
plates were washed four times with PBST and incu-
bated with 100 μlwell of biotinylated-monoclonal
anti-mouse IgA (1 : 500; BD Pharmingen; #556978)
diluted in 1% BSA in PBST for 1 h at 37℃. The wells
were further washed four times with 200 μlwell of
PBST, and 100 μlwell of avidin-horse radish peroxi-
dase (HRP) conjugate (1 : 2000; BD Pharmingen)
were applied onto the plate for 30 min incubation at
37℃. After a final four-wash cycle with PBST, total
IgA binding activity was revealed by addition of 100
μlwell of 3,3’,5,5’-tetramethylbenzidine (TMB) sub-
strate (Sigma-Aldrich). The reaction was terminated
after 30 min by addition of 50 μlwell of 2N H2SO4,
and absorbance values were determined at 450 nm
using an ELISA microplate reader (Bio-Rad Laborato-
ries).
REAL-TIME RT-PCR ANALYSIS OF GENE EX-
PRESSION IN PEYER’S PATCHES
Peyer’s patches from two mice were pooled within
each group (n = 6 samples per group). Total RNA was
extracted from Peyer’s patches using Aurum total
RNA mini kit (Bio-Rad Laboratories). The total RNA
integrity was assessed on 1% agarose gels, and re-
spective concentrations and purity were determined
with Nanodrop 8000 (NanoDrop Products, Wilming-
ton, DE, USA). The cDNA was synthesized from 1.0
μg of total RNA using qScript cDNA Synthesis kit
(Quanta BioSciences, Gaithersburg, MD, USA) fol-
lowing the manufacture’s instruction. The real-time
PCR reactions were performed with SYBR Green I
Detection kit (Quanta BioSciences) using an iCycler
iQ Real Time PCR System (Bio-Rad Laboratories).
The temperature profile was 95℃ for 15 min, then 15
s at 95℃, 56℃ for 15 s and 72℃ for 30 s, repeated for
40-50 cycles. Melt curve analysis was conducted to
confirm the specificity of each product. The target
gene expression was normalized with that of glyce-
raldehyde-3-phosphate dehydrogenase (GAPDH)
gene and relative gene expression was determined
using R = 2(Ct (reference)−Ct (test)).18 Threshold cycle (Ct)
values were obtained at the cycle number at which
the gene is amplified beyond the threshold of 30 fluo-
rescence units. Real-time PCR efficiencies were ac-
quired by amplification of dilution series of cDNA ac-
cording to the equation 10(−1slope).19 The efficiencies
of all primers used in this study were between 96-
105%. Each sample was analyzed in duplicate for each
gene. The sequences of the primers used for real-
time RT-PCR analyses are shown in Table 1.
STATISTICAL ANALYSIS
All data were expressed as means ± SEM and sub-
jected to ANOVA analysis followed by post hoc multi-
ple comparison using Tukey’s test. Comparison of all
the endpoint differences with a level of P < 0.05 was
considered significant. Statistical calculations were
performed using the GraphPad Prism 5.0 package
(GraphPad Software Inc., San Diego, CA, USA).
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Table　1　Sequences of primers used in RT-PCR analyses in this study
Mouse Gene Sequence (5’-3’) Tm value PCR product size Accession number
IL-4 FP: CCTCACAGCAACGAAGAACA 60.02 155 bp NM_021283
RP: ATCGAAAAGCCCGAAAGAGT 60.21
IL-17A FP: CCAGGGAGAGCTTCATCTGT 59.4 125 bp NM_010552
RP: AGGAAGTCCTTGGCCTCAGT 60.25
GAPDH FP: AACTTTGGCATTGTGGAAGG 59.97 132 bp NM_008084
RP: GGATGCAGGGATGATGTTCT 59.89
FP, forward primer; RP, reverse primer; Tm, melting temperature; IL4, interleukin-4; IL17A, interleukin 17A; GAPDH, glyceraldehyde-
3-phosphate dehydrogenase.
Fig.　2　(a) Determination of sneezing frequency in mice during 5 min post challenge by crude 
pollen allergen at the end point. Data are represented as mean ± SEM (n = 12 mice per group). (b) 
Histamine concentration in mouse serum determined by ELISA at the end point. Two serum sam-
ples were pooled in each group and data are represented as mean ± SEM (n = 6). (c) Mouse mast 
cell protease concentration determined in mouse serum by ELISA at end point. Different asterisks 
indicate statistically signifi cant differences at P < 0.05.
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RESULTS
REDUCTION IN FREQUENCY OF CLINICAL
SIGNS AND HISTAMINE CONCENTRATION
Mice in both low and high dose MNB groups had sig-
nificantly reduced (P < 0.05) sneezing frequency as
compared to mice in the positive control group (Fig.
2a). However, there was no difference (P > 0.05) in
sneezing frequency among MNB treatment groups
and negative control, group. Mice in MNB treated
groups and negative control groups also had lower (P
< 0.05) serum histamine concentration (Fig. 2b) and
less mMCPT-1 concentration (P < 0.05) as compared
to the positive control group (Fig. 2c).
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Fig.　3　Serum total IgE (a) and IgG (b) concentration post challenge by pollen allergen at the 
end point. Two serum samples were pooled in each group and concentration of serum total IgE 
and IgG were measured by ELSA. Data are represented as mean ± SEM (n = 6). (c) Total IgA 
concentration in the mice fecal extracts at the endpoint of experiment. Data are represented as 
mean ± SEM (n = 3 replicate tests in fecal extracts). Different asterisks indicate statistically signifi -
cant differences at P < 0.05.
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EFFECTS OF ANTIBODY ACTIVITY ON MNB
PRETREATMENT
There was no significant difference in total and spe-
cific IgG and IgE antibody activity (P > 0.05) in the
MNB treated mice as compared to those of the posi-
tive control (Fig. 3a, b). However, total fecal IgA lev-
els were higher in MNB-treated mice as compared
with those of the positive control mice (Fig. 3c).
There were no significant differences (P > 0.05) in
Cry j 1 and Cry j 2-specific IgE (Fig. 4a), specific IgG
(Fig. 4b), specific IgG1 (Fig. 4c) and specific IgG2a
(Fig. 4d) antibody activity in serum of MNB treated
mice as compared to the positive control group. How-
ever, Cry j 1 and Cry j 2 specific fecal IgA antibody ac-
tivity was higher in the MNB-treated mice as com-
pared with those of the positive control mice (Fig.
4e).
CYTOKINE CONCENTRATION IN SPLENOCY-
TES
Analyses of culture supernatants stimulated in vitro
with purified Cry j 1 and Cry j 2 indicated that IL-4
(Th2-biased cytokine) concentrations were signifi-
cantly lower (P < 0.05) in both MNB-administered
groups as compared to mice in positive control group
(Fig. 5a). IFN-γ (Th1-biased cytokine) concentrations
were significantly higher (P < 0.05) in both MNB-
administered groups, compared with mice in positive
control group (Fig. 5b). Also, mice in the high dose
MNB-administered group had higher IL-10 (regula-
tory T-cell biased cytokine) concentration as com-
pared to animals in positive control group (P < 0.05)
(Fig. 5c). However, there was no significant differ-
ence (P > 0.05) in TGF-β (regulatory T cell-based cy-
tokine) concentration (Fig. 5d) and IL-17 concentra-
tion (Fig. 5e) between groups.
CYTOKINE GENE EXPRESSION IN PEYER’S
PATCHES
The mRNA gene expression of IL-4 gene was de-
creased in the Peyer’s patches collected from the low
dose MNB mice as compared to the positive control
and high dose mice (P < 0.05; Fig. 6a). In addition,
the mRNA level of IL-17 was also decreased in the
Peyer’s patches collected from both the high and low
dose group of mice as compared to the positive con-
trol (P < 0.05; Fig. 6b). The mRNA levels of other
genes IL-10, TGF-beta, IFN-gamma, T-bet, foxp3,
GATA-3 and RORyt remained unchanged in the
Peyer’s patches of all treated groups (data not
shown). No significant changes were observed in cy-
tokine expression in the Peyer’s patches collected
Yang C et al.
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Fig.　4　Serum pollen allergen (Cry j 1 and Cry j 2)-specifi c IgE (a), IgG (b), IgG1 (c), and IgG2a 
(d) levels post challenge by pollen allergen at the end point. Every two serum samples were 
pooled in each group and levels of serum specifi c IgE, IgG, IgG1, and IgG2a were measured by 
ELSA. Data are represented as mean ± SEM (n = 6). (e) Specifi c IgA levels in the mouse fecal 
extracts at the endpoint of experiment. Data are represented as mean ± SEM (n = 3 replicate 
tests in fecal extracts). Different asterisks indicate statistically signifi cant differences at P < 0.05.
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from the negative control group (P > 0.05).
DISCUSSION
The present study was undertaken to provide a novel
platform on use of prebiotic dissacharides to attenu-
ate allergic reactions. The research addresses the
contribution of a novel disaacharide, the β-1,4 manno-
biose in lieu of being an immune-modulator in allevi-
ating clinical signs of allergy in a mouse model of pol-
len allergy and to gain further insights into the under-
lying mechanisms by which the disaccharide MNB
exerts an effect. Mice pre-fed with MNB diet before
sensitisation with pollen extract showed a strong re-
duction in the allergic effector response when com-
pared with mice fed PBS. Sneezing frequency is a ma-
jor clinical sign to assess the pollen allergic response
in a given animal model.20 In the present study, MNB
pretreatment significantly decreased the sneezing fre-
quency serum histamine concentration and mast cell
protease enzyme activity in mice, suggesting that
MNB exerts prophylactic effects of Japanese cedar
pollen allergy.
Type 1 allergic diseases including Cj pollinosis are
characterized by allergen-specific immunoglobulin E
(IgE) activity.21 Here, we found that administration of
MNB did not affect the serum Cry j 1 and Cry j 2-
specific IgE, suggesting that the therapeutic effect
MNB on allergy response may be due to inducion of
tolerance via other local regulatory mechanisms, indi-
cating immune regulation. Also, measurements of se-
rum Cry j 1 and Cry j 2-specific IgG, and sub-isotopes
IgG1 and IgG2a, did not differ among treated groups,
which concludes that MNB pretreatment did not af-
fect antibody isotypes. Therefore, it is most likely that
allergic suppression induced by MNB diet protects
against the development of allergic signs, by a non-
antibody isotype-mediated mechanism. It remains
elusive how MNB may exert its effect on the allergic
Prophylactic Treatment for Pollen Allergy
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Fig.　5　Cytokine production of IL-4 (a), IFN-γ (b), IL-10 (c), TGF-β (d) and IL-17 (e) by spleen 
cells stimulated in vitro with pollen allergen (Cry j 1 and Cry j 2). Cytokine levels in the culture 
supernatants were determined by ELISA. Every two spleens were pooled for cell isolation in 
each group. Data are represented as mean ± SEM (n = 6). ND, non-detectable. Different aster-
isks indicate statistically signifi cant differences at P < 0.05.
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effector response since IgG and IgE antibody iso-
types remain unaltered. It has been earlier reported
by El-Naggar et al.,22 that immunotherapy with OVA-
pullulan significantly decreased nasal airway resis-
tance, dye leakage and histamine content in nasal irri-
gation after allergen challenge, but no significant dif-
ference was found in IL-4 and IL-5 mRNA expression
or in specific IgE level among the groups. Also
Nakamoto et al.23 and several others have investi-
gated the effects of allergen immunotherapy on the
nasal responses in guinea pigs with allergic rhinitis
and found no significant differences in the number of
allergen-specific IgE and IgG antibodies. This was
consistent in our case as well in which antibody iso-
type for specific IgE did not differ among treatment
groups. While specific IgE may be used as a useful
marker of allergic respons, it is required however
isn’t mandatory to reflect the actual allergic status,
since more IgE is also observed in the state of clinical
tolerance. In the present study the total IgE differed
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Fig.　6　Messenger RNA expression in Peyer’s patches as 
determined by real-time RT-PCR analyses for IL-4 and IL-
17A. Data are represented as mean ± SEM (n = 6). Different 
asterisks indicate signifi cant differences (P < 0.05), between 
groups of mice.
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among treatment groups, however; other than IgE,
there may be other immuno-regulatory markers re-
sponsible for reduction of sneezing frequency.
There was an increase in both the total and specific
IgA in the high dose treated group and total IgA in-
crease was observed in the low dose treated group as
well. Being the most abundant antibody isotype in
mucosal secretions, IgA is produced by B cell and ex-
ported by the epithelial polymeric Ig receptor
(pIgR)24 and plays an important role in protecting
against infection in the intestinal immune system,
and its production was previously shown to be in-
creased by dietary MNB in chickens infected with
Salmonella enteritidis,13 which is consistent with the
results observed here. Both the low and high MNB
treated groups had reduced sneezing frequency,
however with regards to fecal IgA content the specific
IgA was only increased in the high dose group,
whereas the total IgA was increased in both treated
groups. It remains to be explored in this case the rea-
son for the difference in response between the two
groups. Recent research showed that high intestinal
IgA play an important role in induction of tolerance
and reduced risk of IgE-associated allergic dis-
eases.25,26 Moreover, intestinal IgA synthesis is regu-
lated by T-cell dependent and T-cell independent
mechanism and is necessary for intestinal immunity
homeostasis by selecting and maintaining the appro-
priate microbial composition.27 Therefore, the pro-
phylactic effect of high dose MNB on allergy may be
partially attributed to increased intestinal IgA secre-
tions, indicating an active regulation of the mucosal
immune response occurring at the gut level. It may
be postulated that the modulating effects of these di-
saccharaides are induced by change in gut microflora
or in a microbiota independent mechanism of direct
interaction on cells of the immune system, however
in this study it seems that it may be attributed to the
second mechanism.
The mechanism of pathogenesis of type I allergy is
initiated by phagocytosis of allergens by antigen-
presenting cells (APC), which present antigen to
naïve T cells. Conventional CD4+ T cells can be subdi-
vided into four distinct populations, the T helper type
1 (Th1), T helper type 2 (Th2), T helper 17 (Th17),
and regulatory T (Treg) cells.28 The Th2 cells pre-
dominantly produce interleukin (IL)-4 and IL-5, and
promote IgE synthesis. In contrast, the Th1 cells
mainly secrete cytokines such as IL-2 and interferon
(IFN)-γ, and prevent IgE production.29 The balance
between Th1- and Th2- is thought to be important for
the development of allergy disease and in immune
homeostatis. The Th17 cells mainly secrete IL17A
and Treg cells mainly secrete TGF-β and IL-10.30
Regulatory T cells can regulate the Th1Th2 balance
and suppress the allergic response.17 To clarify the
mechanisms involved in the inhibition of allergy, we
examined cytokine production from spleen cells that
were stimulated with Cry j1 and Cry j 2 in vitro. We
found oral administration of MNB (both low and high
dose) improves Th1Th2 balance by decreasing Th2-
biased cytokine IL-4, and increasing Th1-biased cy-
tokine IFN-γ. The high dose also induced the Treg
cytokine response by increasing IL-10 production,
suggesting that MNB may modulate the Th1Th2
balance by inducing Treg cell differentiation thereby
attenuating the allergy response. However staining
cells for CD25+ Foxp3+ was not done here which are
part of ongoing investigations elucidating further in-
sights into mechanistical evidence of MNB abrogat-
ing allergic suppression, to test if T-regs are directly
involved in suppression of allergic response. Also the
cytokine TGFβ did not differ among groups. This is
not surprising since Bohle et al. earlier reported that
suppression of allergen-specific T cell proliferation
was observed at 4 weeks of birch pollen immunother-
apy mediated by IL-10 but not TGF-beta.31 Similar ob-
servation was made in our study in which the high
Prophylactic Treatment for Pollen Allergy
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dose group had more IL-10 production, but no differ-
ence was observed in TGF-beta production among
groups. It could be that IL-10-producing CD4+ T cells
seen in our study may be a result of expansion of by-
stander cells as described earlier in murine disease
models.32
The Peyer’s patches are the primary site for anti-
gen uptake in the intestine and play an important role
in immune homeostasis.33 The genes T-bet, GATA3,
RORγT, and FoxP3 have emerged as the key tran-
scriptional factors responsible for controlling the fate
of both innate and adaptive immune cells, and its ex-
pression in Th1, Th2, Th17, and Treg cells, respec-
tively.30,34 To clarify the mechanisms involved in the
inhibition of allergy, we also examined the mRNA ex-
pression of cytokines and transcriptional factors in
Peyer’s patches. We found IL-4 mRNA expression
was decreased upon administration of low dose
MNB, suggesting MNB can suppress Th2 response
in the Peyer’s patches in that group. However the
high dose group had increased IL-4 expression. Since
the IL-4 protein concentration was low with both the
treatments, it could be argued that validating IL-4
concentrations at the protein level would seem more
appropriate as compared to the mRNA expression
data. In the present study, administration of MNB de-
creased IL17A mRNA expression suggesting that
MNB suppresses the Th17A response. Recently, IL17
A has been believed to be involved in the pathogene-
sis of allergic diseases and is being targeted as a po-
tential therapeutic candidate for allergy35 and in that
context the reduction of IL-17 expression in both
treatment groups is of interest.
Both the low and high dose of MNB alleviated
clinical signs of pollen allergy using various mecha-
nisms. The low dose group had less histamine, less
mMCPT-1 concentration, less total IgE, more total
IgA, less IL-4, more IFN-γ and less IL-4 and IL-17
mRNA expression. On the other hand the high dose
group showed less histamine, less mMCPT-1 concen-
traion, less total igE, more total and specific IgA, less
IL-4 and more IFN-γ and IL-10 and less IL-17 mRNA
expression. Overall, in conclusion, dietary interven-
tion with MNB significantly attenuated pollen allergic
response by improving Th1Th2 balance, increasing
regulatory T cell response, decreasing Th17 re-
sponse, and increasing IgA production. However,
how MNB interacts with mucosa-associated lym-
phoid tissue (MALT) as well as localregional
mucosa-draining lymph nodes (LNs) by potential re-
ceptors, such as TLR4, is still not clear and further in-
vestigation is needed to be conducted. This study
provides insight into using MNB as a prophylactic im-
mune modulator candidate for suppression of pollen
allergy.
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